Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: sign (706), suggestion (67), signal (63), hint (14), warning (316), clue (3)

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Tru
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Paclitaxel Albumin Bound (Abraxane)

Description: Chemotherapy Protocol BREAST CANCER PACLITAXEL ALBUMIN BOUND Regimen • Breast Cancer – Paclitaxel Albumin Bound Indication • Paclitaxel albumin bound can be prescribed where
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Paclitaxel-Albumin-Bound-Abraxane.pdf

UHS adult major trauma guidelines

Description: Adult Major Trauma Guidelines University Hospital Southampton NHS Foundation Trust Dr Mark Baxter Director of Major Trauma
Url: /Media/SUHTExtranet/WessexTraumaNetwork/UHS-adult-major-trauma-guidelines.pdf

Annual-report-2018-19

Description: ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Apalutamide v1

Description: Chemotherapy Protocol PROSTATE APALUTAMIDE Regimen  Prostate cancer Indication  Apalutamide is recommended for non-metastatic prostate cancer as defined by recent imaging
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Apalutamide-v1.pdf

Ruxolitinib

Description: Chemotherapy Protocol Myelofibrosis Ruxolitinib Regimen • Myelofibrosis – Ruxolitinib Indication • Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myelofibrosis/Ruxolitinib.pdf

Cetuximab-Irinotecan (14 day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (14 day) This regimen may require funding Regimen • Colorectal Cancer–Cetuximab-Irinotecan (14 day) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan14day.pdf

Cetuximab (7 day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB (7 day) This regimen may require funding Regimen • Colorectal Cancer – Cetuximab (7 day) Indication • Metastatic colorectal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab7day.pdf

Bevacizumab-Fluorouracil-Folinic Acid-Oxaliplatin

Description: Chemotherapy Protocol COLORECTAL CANCER BEVACIZUMAB-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)OXALIPLATIN This regimen may require funding Regimen • Colorectal Cancer – Bevacizu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Bevacizumab-Fluorouracil-FolinicAcid-Oxaliplatin.pdf

WGLS (combined) user handbook

Description: University Hospital Southampton NHS Foundation Trust DOC987 Revision 1/ WRGL 33687 V1.0 Wessex Genomics Laboratory Service Wessex Genomics Laboratory Service
Url: /Media/UHS-website-2019/Docs/Services/Pathology/WGLS-combined-user-handbook.pdf

21 to 30 of 643

Previous 1 2 3 4 5 … Next